货号:A335983 同义名:
JNJ 28431754;TA-7284
Canagliflozin (JNJ 28431754)是一种选择性SGLT2抑制剂,其在CHOK细胞中对mSGLT2、rSGLT2和hSGLT2的IC50值分别为2 nM、3.7 nM和4.4 nM。
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | SGLT1 ↓ ↑ | SGLT2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phloretin | ✔ | 98% | |||||||||||||||||
Canagliflozin |
+++
hSGLT2, IC50: 3.7 nM mSGLT2, IC50: 2 nM | 95% | |||||||||||||||||
Empagliflozin |
++
SGLT2, IC50: 3.1 nM | 98% | |||||||||||||||||
Dapagliflozin |
++++
hSGLT2, EC50: 1.1 nM | 97% | |||||||||||||||||
Tofogliflozin (hydrate) |
+++
hSGLT2, IC50: 2.9 nM | 99%+ | |||||||||||||||||
Sotagliflozin |
+
SGLT1, IC50: 36 nM |
++++
SGLT2, IC50: 1.8 nM | 98% | ||||||||||||||||
Ipragliflozin |
++
hSGLT2, IC50: 7.4 nM | 98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Sodium glucose co-transporter 2 (SGLT2) is a high-capacity glucose transporter mediating the majority of the glucose resorption in kidney. Canagliflozin is a selective, potent SGLT2 inhibitor with IC50 values of 4.4, 3.7, and 2.0 nM for human SGLT2, rat SGLT2, and mouse SGLT2, respectively. In contrast, canagliflozin inhibited human, rat and mouse SGLT1 with IC50 values of 684, 571, and >1000 nM, respectively. In L6 myoblasts, canagliflozin at 10 μM blocked the non-Na+-linked GLUT-mediated 3H-2-DG uptake by < 50%. Canagliflozin at 10 μM inhibited DNJ-induced currents by 23.4% in SGLT3-injected oocytes, whereas the same treatment of canagliflozin had no effect on currents in water-injected oocytes. In Zucker diabetic fatty (ZDF) rats treated by 1 mg/kg canagliflozin hemihydrate, renal threshold for glucose excretion was reduced from 415 mg/dl to 94 mg/dl at 90 min post treatment. In db/db mice, single dose of canagliflozin (1 and 10 mg/kg) rapidly downregulated non-fasting blood glucose concentration in a dose-dependent manner at 1h post treatment. When ZDF rats were treated with canagliflozin at different doses (3, 10, or 30 mg/kg) for 4 weeks, the non-fasting blood glucose and the level of HbA1c were decreased in all canagliflozin hemihydrate-treated rats compared to control group. Decreased blood glucose level following an oral glucose tolerance test was also observed in canagliflozin hemihydrate-treated rats. Treatment of 30 mg/kg canagliflozin in DIO mice for 4 weeks decreased their blood glucose level, respiratory exchange ratio, and body weight gain compared to vehicle-treated mice[2]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
CHO-K1 cells | Function assay | Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay, IC50=6.7 nM | 22652255 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02053116 | Type 2 Diabetes Mellitus | Phase 2 | Terminated(On 25April2014, stu... 展开 >>dy was terminated before any dosing due to an AE of safety concern that occurred in protocol B1731003 with the same drug.) 收起 << | - | United States, Florida ... 展开 >> Pfizer Investigational Site DeLand, Florida, United States, 32720 收起 << |
NCT00650806 | - | Completed | - | - | |
NCT01273558 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
计算器 | ||||
存储液制备 | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 2.25mL 0.45mL 0.22mL | 11.25mL 2.25mL 1.12mL | 22.50mL 4.50mL 2.25mL |
CAS号 | 842133-18-0 |
分子式 | C24H25FO5S |
分子量 | 444.52 |
别名 | JNJ 28431754;TA-7284;JNJ-24831754 |
运输 | 蓝冰 |
存储条件 | In solvent -20°C:3-6个月-80°C:12个月 Pure form Keep in dark place,Inert atmosphere,2-8°C |
溶解方案 | DMSO: 50 mg/mL(112.48 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 | 0.5% CMC+0.25% Tween 80+water 18 mg/mL suspension |
Tags: Canagliflozin | JNJ 28431754;TA-7284;JNJ-24831754 | SGLT | AmBeed-信号通路专用抑制剂 | Canagliflozin 纯度/质量文件 | Canagliflozin 亚型比较 | Canagliflozin 生物活性 | Canagliflozin 细胞研究 | Canagliflozin 临床数据 | Canagliflozin 实验方案 | Canagliflozin 技术信息
请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.
靶点 | 数值 |
SGLT2 |
hSGLT2, IC50:3.7 nM mSGLT2, IC50:2 nM |
需要的总药量: mg
您需要配制的工作液浓度为:mg/mL
细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
CHO-K1 cells | Function assay | Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay, IC50=6.7 nM | 22652255 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02053116 | Type 2 Diabetes Mellitus | Phase 2 | Terminated(On 25April2014, stu... 展开 >>dy was terminated before any dosing due to an AE of safety concern that occurred in protocol B1731003 with the same drug.) 收起 << | - | United States, Florida ... 展开 >> Pfizer Investigational Site DeLand, Florida, United States, 32720 收起 << |
NCT00650806 | - | Completed | - | - | |
NCT01273558 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
NCT01756404 | Healthy | Phase 1 | Completed | - | United States, Florida ... 展开 >> Miramar, Florida, United States 收起 << |
NCT00650806 | Obesity | Phase 2 | Completed | - | - |
NCT02920918 | Heart Failure, Systolic ... 展开 >> Diabetes Mellitus, Type 2 收起 << | Phase 4 | Active, not recruiting | March 2019 | United States, Virginia ... 展开 >> Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 << |
NCT02681497 | - | Completed | - | Canada, Ontario ... 展开 >> Western University London, Ontario, Canada, N6A 3K7 收起 << | |
NCT01714206 | Healthy | Phase 1 | Completed | - | - |
NCT01032629 | Diabetes Mellitus, Type 2 ... 展开 >> Cardiovascular Diseases Risk Factors 收起 << | Phase 3 | Completed | - | - |
NCT01459094 | Healthy | Phase 1 | Completed | - | - |
NCT02737657 | - | Completed | - | Kuwait ... 展开 >> Kuwait City, Kuwait Lebanon Amioun, Lebanon Beirut, Lebanon Nabatieh, Lebanon Saida, Lebanon Taalabya, Lebanon Tripoli, Lebanon United Arab Emirates Al Ain, United Arab Emirates Dubai, United Arab Emirates 收起 << | |
NCT02220907 | - | Completed | - | - | |
NCT02220907 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Research site Chubu, Japan Research site Chugoku, Japan Research site Hokkaido, Japan Research site Kanto, Japan Research site Kyushu, Japan Research site Tohoku, Japan 收起 << |
NCT01032629 | - | Completed | - | - | |
NCT01463774 | Healthy | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT02354222 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Reserch site Kanto, Japan Reserch site Kinki, Japan Reserch site Tohoku, Japan 收起 << |
NCT02354222 | - | Completed | - | - | |
NCT01665638 | Healthy | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
NCT02846506 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT02851212 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT02694263 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | September 2018 | United Kingdom ... 展开 >> University Hospitals of Leicester NHS Trust Recruiting Leicester, Leicestershire, United Kingdom, LE5 4PW Contact: Emer Brady, PhD 0116248 ext 8959 emer.brady@uhl-tr.nhs.uk Contact: Natasha Wileman, MSc 0116258 ext 8929 natasha.wileman@uhl-tr.nhs.uk University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, West Midlands, United Kingdom, B15 2TH Contact: Wasim Hanif 0121371 ext 4404 wasim.hanif@uhb.nhs.uk Contact: Deborah Smith 0121371 ext 4707 deborah.smith@uhb.nhs.uk 收起 << |
NCT00968812 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT00968812 | - | Completed | - | - | |
NCT03267576 | Diabetes Mellitus, Type 2 | Phase 4 | Completed | - | Mexico ... 展开 >> Consultorio Privado Guadalajara, Mexico, 44150 Investigación Clínica Especializada Guadalajara, Mexico, 44600 Consultorio Privado en Unidad de Patología Clínica Guadalajara, Mexico, 44650 Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán Mexico City, Mexico, 14080 Hospital Universitario 'Dr. Jose Eleuterio Gonzalez' Monterrey, Mexico, 64460 收起 << |
NCT01787357 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01916863 | Healthy Subjects | Phase 1 | Completed | - | United States, California ... 展开 >> Lexicon Investigational Site Chula Vista, California, United States, 91911 收起 << |
NCT01106677 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01748526 | Healthy | Phase 1 | Completed | - | India ... 展开 >> Ahmedabad, India 收起 << |
NCT01759576 | Renal Insufficiency ... 展开 >> Healthy 收起 << | Phase 1 | Completed | - | United States, Florida ... 展开 >> Orlando, Florida, United States United States, Minnesota Minneapolis, Minnesota, United States United States, Tennessee Knoxville, Tennessee, United States 收起 << |
NCT01381887 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | United States, California ... 展开 >> Chula Vista, California, United States United States, Florida Miramar, Florida, United States United States, Ohio Cincinnati, Ohio, United States United States, Texas Dallas, Texas, United States San Antonio, Texas, United States 收起 << |
NCT02851095 | Healthy | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT02865668 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01106690 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT02220920 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Japan ... 展开 >> Reserch site Chubu, Japan Reserch site Chugoku, Japan Reserch site Hokkaido, Japan Reserch site Kanto, Japan Reserch site Kinki, Japan Reserch site Kyushu, Japan Reserch site Tohoku, Japan 收起 << |
NCT02220920 | - | Completed | - | - | |
NCT02360774 | - | Completed | - | - | |
NCT01821027 | Healthy | Phase 1 | Completed | - | - |
NCT01483781 | Diabetes Mellitus, Type 2 ... 展开 >> Plasma Volume 收起 << | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
NCT01106677 | - | Completed | - | - | |
NCT01137812 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01137812 | - | Completed | - | - | |
NCT03136484 | Diabetes Diab... 展开 >>etes Mellitus, Type 2 收起 << | Phase 3 | Completed | - | - |
NCT02025907 | - | Completed | - | - | |
NCT01106690 | - | Completed | - | - | |
NCT02025907 | Diabetes Mellitus, Type 2 | Phase 4 | Completed | - | - |
NCT01106625 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT02360774 | Type 2 Diabetes ... 展开 >> Overweight Obesity 收起 << | Phase 4 | Completed | - | United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 收起 << |
NCT01173549 | Healthy | Phase 1 | Completed | - | United States, California ... 展开 >> La Jolla, California, United States 收起 << |
NCT01106625 | - | Completed | - | - | |
NCT02462421 | Diabetes Mellitus ... 展开 >> Gout Hyperuricemia 收起 << | Phase 4 | Enrolling by invitation | September 2019 | - |
NCT01508182 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01508195 | Healthy | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT01756417 | Healthy | Phase 1 | Completed | - | United States, New Jersey ... 展开 >> Neptune, New Jersey, United States 收起 << |
NCT02009488 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | United States, California ... 展开 >> San Diego, La Jolla, California, United States United States, Florida Gainesville, Florida, United States 收起 << |
NCT02039258 | Healthy Volunteers | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT01106651 | - | Completed | - | - | |
NCT01106651 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01081834 | - | Completed | - | - | |
NCT01939496 | - | Completed | - | - | |
NCT01989754 | Diabetes Mellitus, Type 2 ... 展开 >> Albuminuria 收起 << | Phase 4 | Completed | - | - |
NCT01939496 | Diabetes Mellitus, Type 2 ... 展开 >> Hypertension 收起 << | Phase 4 | Completed | - | - |
NCT01733108 | Healthy | Phase 1 | Completed | - | - |
NCT01081834 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01809327 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01989754 | - | Completed | - | - | |
NCT02077803 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT02354235 | - | Completed | - | - | |
NCT02354235 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Reserch site Kanto, Japan Reserch site Kinki, Japan Reserch site Tohoku, Japan 收起 << |
NCT02071368 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01281579 | Healthy | Phase 1 | Completed | - | - |
NCT01381900 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | China ... 展开 >> Baotou, China Beijing, China Changchun, China Changsha, China Chengdu, China Chongqing, China Guangzhou, China Hangzhou, China Harbin, China Nanchang, China Nanjing, China Nanning, China Shanghai, China Shenyang, China Shiyan, China Siping, China Su Zhou, China Tianjin, China Wuxi, China Xi'An, China Malaysia Kota Bharu, Malaysia Pulau Pinang, Malaysia Selangor, Malaysia Vietnam Hanoi, Vietnam Ho Chi Minh, Vietnam 收起 << |
NCT01809327 | - | Completed | - | - | |
NCT02065791 | Diabetes Mellitus, Type 2 ... 展开 >> Diabetic Nephropathy 收起 << | Phase 3 | Active, not recruiting | June 28, 2019 | - |
NCT01381900 | - | Completed | - | - | |
NCT01463228 | Healthy | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT01454622 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT02404870 | Diabetes PTH ... 展开 >> Vitamin D Fibroblast Growth Factor (FGF23) Phosphate 收起 << | Phase 1 | Recruiting | May 1, 2019 | United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov 收起 << |
NCT01195324 | Healthy | Phase 1 | Completed | - | Belgium ... 展开 >> Merksem, Belgium 收起 << |
NCT01791231 | Healthy | Phase 1 | Completed | - | Belgium ... 展开 >> Merksem, Belgium 收起 << |
NCT01286103 | Healthy | Phase 1 | Completed | - | - |
NCT01128985 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | United States, Florida ... 展开 >> Fort Myers, Florida, United States Miramar, Florida, United States 收起 << |
NCT02065752 | Healthy Volunteers | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT02227849 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Japan ... 展开 >> Reserch site Chubu, Japan Reserch site Hokkaido, Japan Reserch site Kanto, Japan Reserch site Kinki, Japan 收起 << |
NCT01340664 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
NCT01518712 | Healthy | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01340664 | - | Completed | - | - | |
NCT02622113 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Japan ... 展开 >> Reserch site Chubu, Japan Reserch site Chugoku, Japan Reserch site Hokkaido, Japan Reserch site Kanto, Japan Reserch site Kinki, Japan Reserch site Kyushu, Japan Reserch site Tohoku, Japan 收起 << |
NCT02688075 | - | Completed | - | Canada, Alberta ... 展开 >> Calgary, Alberta, Canada Edmonton, Alberta, Canada Canada, British Columbia Coquitlam, British Columbia, Canada Surrey, British Columbia, Canada Canada, Manitoba Winnipeg, Manitoba, Canada Canada, Ontario Brampton, Ontario, Canada Downsview, Ontario, Canada Guelph, Ontario, Canada London, Ontario, Canada Mississauga, Ontario, Canada Ohsweken, Ontario, Canada Ottawa, Ontario, Canada Smiths Falls, Ontario, Canada Toronto, Ontario, Canada Canada, Quebec Laval, Quebec, Canada Longueuil, Quebec, Canada Montreal, Quebec, Canada Saint-Jean-Sur-Richelieu, Quebec, Canada Sherbrooke, Quebec, Canada St Marc Des Carrieres, Quebec, Canada Toronto, Quebec, Canada Westmont, Quebec, Canada Canada, Saskatchewan Saskatoon, Saskatchewan, Canada 收起 << | |
NCT02039245 | Healthy Volunteers | Phase 1 | Completed | - | United States, New Jersey ... 展开 >> Neptune, New Jersey, United States 收起 << |
NCT01064414 | Diabetes Mellitus, Type 2 ... 展开 >> Renal Insufficiency 收起 << | Phase 3 | Completed | - | - |
NCT01294631 | Healthy | Phase 1 | Completed | - | - |
NCT01395927 | Healthy | Phase 1 | Completed | - | United States, Kansas ... 展开 >> Overland Park, Kansas, United States 收起 << |
NCT01340677 | Healthy | Phase 1 | Completed | - | Belgium ... 展开 >> Merksem, Belgium 收起 << |
NCT01064414 | - | Completed | - | - | |
NCT01714193 | Healthy | Phase 1 | Completed | - | - |
NCT03170518 | Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | June 30, 2021 | - |
NCT01273571 | Healthy | Phase 1 | Completed | - | - |
NCT01343290 | Healthy | Phase 1 | Completed | - | - |
NCT02243202 | Obesity | Phase 2 | Completed | - | United States, Arizona ... 展开 >> Phoenix, Arizona, United States United States, California Walnut Creek, California, United States United States, Florida Jacksonville, Florida, United States United States, Idaho Meridian, Idaho, United States United States, Indiana Evansville, Indiana, United States United States, Kentucky Lexington, Kentucky, United States Louisville, Kentucky, United States United States, Louisiana New Orleans, Louisiana, United States United States, Massachusetts Milford, Massachusetts, United States United States, New York Manlius, New York, United States United States, Rhode Island Warwick, Rhode Island, United States United States, South Carolina Mt Pleasant, South Carolina, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States Odessa, Texas, United States United States, Virginia Norfolk, Virginia, United States United States, Wisconsin Wauwatosa, Wisconsin, United States 收起 << |
NCT02139943 | - | Completed | - | - | |
NCT02964585 | Type 2 Diabetes Mellitus | Phase 4 | Recruiting | May 2019 | United States, District of Col... 展开 >>umbia The George Washington University Medical Faculty Associates Recruiting Washington, District of Columbia, United States, 20037 Contact: Fiona Dore, BS 202-741-2342 fdore@mfa.gwu.edu 收起 << |
NCT02221180 | Bioequivalence | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT03298009 | Type2 Diabetes ... 展开 >> Heart Failure 收起 << | Not Applicable | Withdrawn(end of contract nego... 展开 >>ciations) 收起 << | January 1, 2019 | - |
NCT02139943 | Diabetes Mellitus, Type 1 | Phase 2 | Completed | - | - |
NCT01428284 | Healthy | Phase 1 | Completed | - | United States, Kansas ... 展开 >> Overland Park, Kansas, United States 收起 << |
NCT02073227 | Healthy Volunteers | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Tempe, Arizona, United States 收起 << |
NCT01707316 | Healthy | Phase 1 | Completed | - | China ... 展开 >> Beijing, China 收起 << |
NCT02243202 | - | Completed | - | - | |
NCT03436693 | Diabetic Nephropathy | Phase 3 | Recruiting | September 2021 | Japan ... 展开 >> Research site Recruiting Aichi, Japan Research site Recruiting Chiba, Japan Research site Recruiting Fukuoka, Japan Research site Recruiting Fukushima, Japan Research site Recruiting Gunma, Japan Research site Recruiting Hiroshima, Japan Research site Recruiting Hokkaido, Japan Research site Recruiting Hyogo, Japan Research site Recruiting Ibaraki, Japan Research site Recruiting Kagawa, Japan Research site Recruiting Kagoshima, Japan Research site Recruiting Kanagawa, Japan Research site Recruiting Kumamoto, Japan Research site Recruiting Mie, Japan Research site Recruiting Nagano, Japan Research site Recruiting Nagasaki, Japan Research site Recruiting Oita, Japan Research site Recruiting Okinawa, Japan Research site Recruiting Osaka, Japan Research site Recruiting Saitama, Japan Research site Recruiting Shizuoka, Japan Research site Recruiting Tochigi, Japan Research site Recruiting Tokyo, Japan Research site Recruiting Wakayama, Japan Research site Recruiting Yamagata, Japan Research site Recruiting Yamaguchi, Japan 收起 << |
NCT02220218 | Healthy | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Lincoln, Nebraska, United States 收起 << |
NCT02597309 | Diabetes, Obesity | Phase 4 | Withdrawn | July 2017 | United States, Massachusetts ... 展开 >> Joslin Diabetes Center Boston, Massachusetts, United States, 02215 收起 << |
NCT02324842 | Type 2 Diabetes Mellitus | Not Applicable | Recruiting | December 2018 | United States, Texas ... 展开 >> University of Texas Health Science Center at San Antonio Recruiting San Antonio, Texas, United States, 78229 Contact: Ralph A DeFronzo, MD 210-567-6691 defronzo@uthscsa.edu Contact: Monica Palomo, BS 210-567-6710 palomom@uthscsa.edu Principal Investigator: Ralph A DeFronzo, MD 收起 << |
NCT01186588 | Healthy Hepat... 展开 >>ic Insufficiency 收起 << | Phase 1 | Completed | - | United States, Florida ... 展开 >> Orlando, Florida, United States United States, Tennessee Knoxville, Tennessee, United States 收起 << |
NCT01877889 | Healthy | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
NCT03604224 | - | Recruiting | March 29, 2019 | India ... 展开 >> Diacon Hospital Recruiting Bangalore, India, 560010 Dr. A. Ramachandran's Diabetes Hospitals Not yet recruiting Chennai, India, 600032 CARE Hospitals Not yet recruiting Hydrabad, India, 500001 收起 << | |
NCT02624908 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | November 2018 | United States, Georgia ... 展开 >> Atlanta VA Medical Center Recruiting Decatur, Georgia, United States, 30033 收起 << |
NCT01718652 | Healthy | Phase 1 | Completed | - | Belgium ... 展开 >> Antwerpen, Belgium 收起 << |
NCT03190798 | Type2 Diabetes Mellitus ... 展开 >> Cardiovascular Diseases 收起 << | Phase 4 | Withdrawn(Study has been withd... 展开 >>rawn from IRB review pending IND revision) 收起 << | August 1, 2018 | United States, Texas ... 展开 >> The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 收起 << |
NCT02891954 | Diabetes Mellitus, Type 2 | Phase 1 | Enrolling by invitation | June 30, 2023 | - |
NCT02673138 | Type 1 Diabetes | Not Applicable | Completed | - | United States, Connecticut ... 展开 >> Yale University School of Medicine New Haven, Connecticut, United States, 06520 收起 << |
NCT02673138 | - | Completed | - | - | |
NCT02000700 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | United States, Arkansas ... 展开 >> Little Rock, Arkansas, United States United States, California Los Angeles, California, United States United States, Colorado Aurora, Colorado, United States United States, Connecticut New Haven, Connecticut, United States United States, Florida Jacksonville, Florida, United States United States, Indiana Indianapolis, Indiana, United States United States, Kansas Lenexa, Kansas, United States United States, Maryland Baltimore, Maryland, United States United States, Missouri Kansas City, Missouri, United States United States, Ohio Toledo, Ohio, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Texas Houston, Texas, United States United States, Utah Salt Lake City, Utah, United States Brazil Campinas, Brazil Curitiba, Brazil Ribeirão Preto, Brazil Sao Paulo, Brazil 收起 << |
NCT01157000 | Healthy | Phase 1 | Completed | - | Belgium ... 展开 >> Merksem, Belgium 收起 << |
NCT02912455 | Diabetes Mellitus, Type 2 ... 展开 >> Obesity 收起 << | Phase 4 | Recruiting | July 31, 2018 | United States, Ohio ... 展开 >> Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Sangeeta Kashyap, MD 216-445-2679 kashyas@ccf.org Contact: Mario Scarcipino 216-444-3599 mascar@ccf.org Principal Investigator: Sangeeta Kashyap, MD 收起 << |
尊敬的 Ambeed 客户您好,
请您选择所在区域,我们将转接对应客服为您服务!